Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Journal of Surgical Oncology|January 1, 1979
Immunotherapy of a murine sarcoma using specific antitumor immune RNAD J Webster, J B Cornacoff, D A Vallera, et al.
American Journal of Surgery|September 1, 1987
Needle localization of mammographically detected lesions in perspectiveB J Sickle-Santanello, P J O'Dwyer, D P McCabe, et al.
Oncology|January 1, 1975
Combination chemotherapy in breast cancer: a randomized study of 4 versus 5 drugsG Ramirez, J Klotz, J G Strawitz, et al.
Cancer|June 1, 1981
DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040G J Hill, S E Moss, F M Golomb, et al.
Journal of Surgical Oncology|July 1, 1989
The use of a hand-held gamma detector improves the safety of isolated limb perfusionA Sardi, J P Minton, C Mojzisik, et al.
Scandinavian Journal of Gastroenterology. Supplement|January 1, 1986
The response of a non-functional VIP- and somatostatin-containing tumour to tolbutamide in vitroE A Woltering, T M O'Dorisio, H S Mekhjian, et al.
Journal of Surgical Oncology|January 1, 1979
5-FU versus combination therapy with tubercidin, streptozotocin, and 5-FU in the treatment of pancreatic carcinomas: COG protocol 7230A Awrich, W S Fletcher, J H Klotz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1993
One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group studyS E Rivkin, S Green, B Metch, et al.
Cancer Treatment Reports|May 1, 1976
DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065)R D Carter, E T Krementz, G J Hill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group studyS E Rivkin, S Green, B Metch, et al.
Pageof 9